RE:RE:RE:RE:RE:RE:Companies now seek to moderate TME to expand PD-(L)1 effectTinurilimab (Bay 1834942) is an anti-CEACAM6 monoclonal antibody and was demonstrated to be equally efficacious compared to blockade of PD-L1, (which was not enhanced by ONCY's pelareorep) and the anti-CEACAM6 mab showed an additive efficacy when combined with anti-PD-1 or anti-TIM-3 antibodies, suggesting an efficacy independent of the PD-1/PD-L1 axis, in contrast to ONCY's pelareorep which has demonstrated to be synergistic with anti PD-(L)1 and anti-TIM-3 antibodies.
So this suggests that an anti-CEACAM6 mab + pelareorep + anti-PD(L)1 antibody triplet could be a potential immuno-oncology drug combination for use in the treatment of pancreatic cancer. A potential issue for such a triplet could be safety and tolerability but that could be possibly overcome with sequencing and dosing.